Lifeboat Foundation

A lot of anti-ageing vids lately. Good. This concerns Turn.bio. Though not in this vid, MH does have a habit of asking ‘When?” at some point. Previously Turn.bio said they have a first working treatment in just a few years so we’ll see what happens in vids to come of this interview.

In this video Professor Sebastiano introduces ERA, Epigenetic Reprogramming of Age technology and talks about his thoughts on some of the causes of aging.

Continue reading “Age Reversal” »

The announcement comes from the journal Science, which published Phase 1 results of a small clinical trial for a vaccine technology that aims to cause the body to create a rare kind of cell.

“At the most general level, the trial results show that one can design vaccines that induce antibodies with pre-specified genetic features, and this may herald a new era of precision vaccines,” William Schief, PhD, a researcher at The Scripps Research Institute and study co-author, told the American Association for the Advancement of Science (AAAS).

The study was the first to test the approach in humans and was effective in 97% – or 35 of 36 – participants. The vaccine technology is called “germline targeting.” Trial results show that “one can design a vaccine that elicits made-to-order antibodies in humans,” Schief said in a news release.

The key to curing cancer may be hidden within the genetic differences between humans and dogs. According to scientists working with the National Institutes of Health, dogs get the same diseases that we do, and they have many of the same genes that we do, too.

This is a followup trial result to the first trial that reported 2.5 years of epigenetic age reversal This has interesting reports from the actual patients about how they feel and the changes it made to them. After the first trial I sent an email to see if I could do this but I have IBS which Fahy said would disqualify me.

Dr. Greg Fahy gives an update on the TRIIM-X clinical trial at EARD 2022.

Continue reading “The Thymus As A Key Target For Aging Intervention — Dr. Greg Fahy — EARD 2022” »

Join us on Patreon!
https://www.patreon.com/MichaelLustgartenPhD

TruDiagnostic Discount Link (Epigenetic Testing)
CONQUERAGING!
https://bit.ly/3Rken0n.

Continue reading “Methionine Restriction Extends Lifespan: Roles For SCFAs And FGF21, But Not Calorie Restriction” »

A gene linked to autism spectrum disorders plays a critical role in early brain development and may shape the formation of both normal and atypical nerve connections in the brain, according to a new study by Weill Cornell Medicine investigators.

The study, published Nov. 28 in Neuron, employed a combination of sophisticated genetic experiments in mice and analysis of human brain imaging data to better understand why mutations in a gene called Gabrb3 are linked to a high risk of developing autism spectrum disorder (ASD) and a related condition called Angelman Syndrome. Both conditions involve abnormal behaviors and unusual responses to sensory stimuli, which appear to stem, at least in part, from the formation of atypical connections between neurons in the brain.

“Neuron al connections in the brain, and developmental synchronization of neuronal networks, are perturbed in individuals with autism spectrum disorders, and there are specific genes that are implicated in the pathogenesis of ASD,” said co-first author Dr. Rachel Babij, a former student in the Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD-Ph. D. program in the laboratory of Natalia De Marco García, an associate professor in the Feil Family Brain and Mind Research Institute at Weill Cornell Medicine.

For several years now, the CRISPR/Cas9 gene scissors have been causing a sensation in science and medicine. This new tool of molecular biology has its origins in an ancient bacterial immune system. It protects bacteria from attack by so-called phages, i. e. viruses that infect bacteria. Researchers from the Institute of Structural Biology at the University Hospital Bonn (UKB) and the Medical Faculty of the University of Bonn, in cooperation with the partner University of St Andrews in Scotland and the European Molecular Biology Laboratory in Hamburg, have now discovered a new function of the gene scissors. The study was published yesterday in the renowned scientific journal “Nature”.

Bacteria and phages have been engaged in a life-and-death struggle on Earth since time immemorial. When an attacking phage injects its genetic material into a bacterium, it is forced to produce new phages, which in turn infect more bacteria. Some bacteria have evolved the CRISPR system in response. With this bacterial immune system, the phage genetic material is recognized and destroyed.

At the same time, the resulting fragments are integrated into the genome of the bacterium. This creates a kind of library that the CRISPR immune system can access again and again and is thus armed for future attacks. In addition, it was discovered that so-called type III variants of the gene scissors produce small signal molecules. With the help of these small molecules, the bacteria switch on a complex emergency plan. This ensures that a virus can be combated optimally and on a broad front.

Cajal Neuroscience, a biotechnology company integrating human genetics, functional genomics and advanced microscopy to discover novel targets and therapeutics for neurodegeneration, has launched with the completion of a $96 million Series A financing.

The financing was led by The Column Group and Lux Capital, with additional participation from Two Sigma Ventures, Evotec, Bristol Myers Squibb, Alexandria Venture Investments, Dolby Family Ventures and other investors.

Longevity. Technology: Seattle-based Cajal is committed to discovering novel therapeutics for neurodegeneration; by focusing on the mechanistic, spatial and temporal complexity of neurodegeneration, the biotech’s powerful platform is designed to unlock the complexity of disease at unprecedented scale, and integrates expertise in neuroscience, neuroanatomy and computational biology with state-of-the-art technologies for high-throughput functional validation.

The researchers discovered a mutation in the thrombospondin-1 (THBS1) gene in three ethnically and geographically diverse families with a history of childhood glaucoma using advanced genome-sequencing technology. The researchers then confirmed their findings in a mouse model that had the genetic mutation and developed glaucoma symptoms due to a previously unknown disease mechanism.

ALSO READ: Check out these easy eye care tips to keep your eyes healthy as you age

This increase in pressure not only damages the optic nerve but can also affect other structures in a child’s eye like the cornea. Children with childhood glaucoma typically require surgeries as early as the first three to six months of life, followed by several more operations throughout their childhood.